Stock Research: Corcept Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Corcept Therapeutics

NasdaqCM:CORT US2183521028
27
  • Value
    35
  • Growth
    79
  • Safety
    Safety
    1
  • Combined
    15
  • Sentiment
    37
  • 360° View
    360° View
    27
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Corcept Therapeutics Incorporated is a commercial-stage company that develops medications to treat severe disorders by modulating the effects of the hormone cortisol. The company operates in the pharmaceutical industry, marketing Korlym (mifepristone) in the United States. In the last fiscal year, the company had a market cap of $7,599 million, profits of $664 million, and revenue of $675 million with 500 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock Corcept Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Corcept Therapeutics. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 79% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 1 means that the share price of Corcept Therapeutics is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 99% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 35, which means that the company has a riskier financing structure than 65% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 37, indicating professional investors are more pessimistic about the stock than for 63% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 1 1 19
Growth
79 100 91 29
Safety
Safety
35 35 99 99
Sentiment
37 84 61 62
360° View
360° View
27 27 16 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 75 44 13
Opinions Change
31 72 25 50
Pro Holdings
n/a 82 73 98
Market Pulse
44 35 62 52
Sentiment
37 84 61 62
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 1 1 19
Growth
79 100 91 29
Safety Safety
35 35 99 99
Combined
15 15 74 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
23 27 19 52
Price vs. Earnings (P/E)
15 7 18 22
Price vs. Book (P/B)
4 9 9 30
Dividend Yield
1 1 1 1
Value
1 1 1 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
82 81 75 39
Profit Growth
58 74 37 39
Capital Growth
15 100 89 61
Stock Returns
95 100 85 41
Growth
79 100 91 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
19 20 33 41
Liquidity
1 1 86 86
Safety Safety
35 35 99 99

Similar Stocks

Discover high‑ranked alternatives to Corcept Therapeutics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.